Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

Inclusion Criteria: * Patients with surgical wound infection and/or dehiscence * Wound infected by S. aureus and/or P. aeruginosa according to wound swab. * Wound in the groin or any other skin fold as per Investigator's discretion. * Signed Informed Consent Form, approved by the ethical committee and competent authority. * The age between 18 and 75 years. * Patients able and willing to comply with study procedures. * There are no contraindications for planned concomitant medication. * Persisting symptoms of bacterial infection \< 3 weeks since the surgery. * Women of childbearing potential must take highly effective contraceptive measures since the study start and one month after the treatment administration at a minimum. Exclusion Criteria: * History of an organ or bone marrow transplantation. * Any autoimmune disease. * Uncompensated diabetes mellitus, confirmed by the concentration of HbA1c \>60 mmol/mol (6%). * Systematic immunosuppressive therapy. * Malignancy treatment \<1 year before the Baseline visit. * COVID-19 infection \<3 months before the Baseline visit, any signs of post-COVID syndrome. * Pregnancy or planning to become pregnant during the study. * Breastfeeding. * Participation in another clinical study. * Hypersensitivity to the IMP or placebo.